Related Experiment Video
Updated: Jun 16, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Triple-armed oncolytic HSV enhances antitumor immunity by remodeling the tumor microenvironment in subcutaneous
Lei Zhang1, Kunpeng Zheng1, Wu Tong1
1College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang 830046, China.
Abstract:
Colorectal cancer (CRC) is characterized by therapeutic resistance and an immunosuppressive tumor microenvironment (TME). In the present study, five oncolytic herpes simplex virus type 1 (oHSV) variants were constructed based on the herpes simplex virus type 1 (HSV-1) strain 17 via deletion of the IR and ICP47 genes and insertion of the genes encoding mIL-12, mIL-15, and mCCL5. In vitro, these viruses exhibited replication kinetics comparable to those of the wild-type virus, stably expressed the transgenes, and exerted dose- and time-dependent oncolytic effects against colorectal cancer cells. In vivo, the triple-gene-armed oHSV RG2012m remodeled the tumor microenvironment by recruiting and activating immune cells as well as promoting their survival, thereby enhancing antitumor efficacy. Specifically, it elevated the levels of antitumor cytokines and cytotoxic molecules while reducing the abundance of immunosuppressive factors. These oncolytic herpes simplex viruses may function via an "oncolysis-chemotaxis-immune activation" cascade, providing a preclinical rationale for the treatment of colorectal cancer.
Related Concept Videos
Tumor Immunotherapy
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers

